Healthcare · Pharmaceuticals & Biotechnology
QVM read Momentum-led Quality Moderate, Valuation Expensive, Momentum Bullish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #7 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 9 Feb 2024 | Arjun Juneja | Promoter group | Sell | 0 | ₹0 |
| 9 Feb 2024 | Puja Juneja | Promoter group | Sell | 0 | ₹0 |
| 9 Feb 2024 | Sheetal Arora | Promoter | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 14 Oct 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 55,000 | 2430.0000 | NSE |
| 14 Oct 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 55,000 | 2430.0000 | NSE |
| 13 Oct 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 42,245 | 2440.0000 | NSE |
| 13 Oct 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 42,245 | 2440.0000 | NSE |
| 9 May 2025 | GOLDMAN SACHS (SINGAPORE) PTE.- ODI | Block | Buy | 55,000 | 2434.1000 | BSE |
| 9 May 2025 | COPTHALL MAURITIUS INVESTMENT LIMITED | Block | Sell | 55,000 | 2434.1000 | BSE |
| 5 Feb 2025 | ORBIMED GENESIS MASTER FUND L.P. | Block | Buy | 45,000 | 2555.1000 | NSE |
| 5 Feb 2025 | COPTHALL MAURITIUS INVESTMENT LIMITED | Block | Sell | 45,000 | 2555.1000 | NSE |
| 10 Jul 2024 | VERITION MULTI-STRATEGY MASTER FUND LTD. | Block | Buy | 48,032 | 2082.0000 | NSE |
| 10 Jul 2024 | SOCIETE GENERALE | Block | Buy | 120,078 | 2082.0000 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 8 Aug 2025 | Interim Dividend - Re 1 Per Share | 1.0000 | 8 Aug 2025 |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 30 Jul 2026 | Financial Results | Yes |
| 19 May 2026 | Financial Results | Yes |
| 3 Feb 2026 | Financial Results | Yes |
| 6 Nov 2025 | Financial Results | Yes |
| 31 Jul 2025 | Financial Results/Dividend | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 28 Sep 2026 | Company Update | Mankind Pharma Ltd - 543904 - Resignation Of Statutory Auditors Of A Material WOS |
| 28 Sep 2026 | Resignation of Statutory Auditor | Mankind Pharma Limited has informed the Exchange about Resignation of Statutory Auditor |
| 28 Sep 2026 | General Updates | Resignation of Statutory Auditors of a material wholly owned subsidiary company |
| 25 Sep 2026 | Trading Window | Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 25 Sep 2026 | Insider Trading / SAST | Mankind Pharma Ltd - 543904 - Closure of Trading Window |
| 17 Sep 2026 | Shareholders meeting | Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |
| 15 Sep 2026 | Company Update | Mankind Pharma Ltd - 543904 - Intimation Regarding ESG Rating |
| 15 Sep 2026 | General Updates | Mankind Pharma Limited has informed the Exchange about ESG Rating |
| 11 Sep 2026 | Company Update | Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 11 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Mankind Pharma Limited has informed the Exchange about Schedule of meet |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY MIDCAP 100, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY MIDCAP 50, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
